28 related articles for article (PubMed ID: 38453176)
1. Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer-What Can We Learn from Breast Cancer?
Ottenbourgs T; Van Nieuwenhuysen E
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791941
[TBL] [Abstract][Full Text] [Related]
2. A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.
Ottenbourgs T; van Gorp T; Kridelka F; Baert T; Denys H; Selle F; Baas I; Van Rompuy AS; Lambrechts D; Van Nieuwenhuysen E
Int J Gynecol Cancer; 2024 Apr; 34(4):627-630. PubMed ID: 38453176
[TBL] [Abstract][Full Text] [Related]
3. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
McLaughlin PMJ; Klar M; Zwimpfer TA; Dutilh G; Vetter M; Marth C; du Bois A; Schade-Brittinger C; Reuss A; Bommer C; Kurzeder C; Heinzelmann-Schwarz V
BMC Cancer; 2022 May; 22(1):508. PubMed ID: 35524184
[TBL] [Abstract][Full Text] [Related]
5. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
[TBL] [Abstract][Full Text] [Related]
6. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Konstantinopoulos PA; Lee EK; Xiong N; Krasner C; Campos S; Kolin DL; Liu JF; Horowitz N; Wright AA; Bouberhan S; Penson RT; Yeku O; Bowes B; Needham H; Hayes M; Sawyer H; Polak M; Shea M; Cheng SC; Castro C; Matulonis UA
J Clin Oncol; 2023 Jan; 41(3):599-608. PubMed ID: 36174113
[TBL] [Abstract][Full Text] [Related]
7. Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review.
Brink GJ; Groeneweg JW; Hooft L; Zweemer RP; Witteveen PO
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740663
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M;
Gynecol Oncol; 2021 Oct; 163(1):72-78. PubMed ID: 34412908
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
Colon-Otero G; Zanfagnin V; Hou X; Foster NR; Asmus EJ; Wahner Hendrickson A; Jatoi A; Block MS; Langstraat CL; Glaser GE; Dinh TA; Robertson MW; Camoriano JK; Butler KA; Copland JA; Weroha SJ
ESMO Open; 2020 Oct; 5(5):e000926. PubMed ID: 33109627
[TBL] [Abstract][Full Text] [Related]
10. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
[TBL] [Abstract][Full Text] [Related]
11. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
